Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effects of safinamide on pain in patients with fluctuating Parkinson's disease

Sotirios, Grigoriou LU orcid ; Pablo, Martínez Martín ; Ray, Chaudhuri K. ; Katarina, Rukavina ; Valentina, Leta ; Denise, Hausbrand ; Björn, Falkenburger ; Per, Odin LU orcid and Heinz, Reichmann (2021) In Brain and Behavior 11(10).
Abstract

Background: Non-motor symptoms (NMS) are integral to Parkinson's Disease (PD) and management remains a challenge. Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties. Objective: To investigate the efficacy of safinamide on NMS and its burden in PD patients with motor fluctuations after 6 months of treatment. Methods: This observational, multicenter, open-label, pilot study assessed a wide range of NMS using the following rating scales, NMSS (non-motor symptom scale), KPPS (King's PD pain scale), HADS (hospital anxiety and depression scale), PDQ-8 (Parkinson's disease quality of life questionnaire), and PDSS-2 (Parkinson's disease... (More)

Background: Non-motor symptoms (NMS) are integral to Parkinson's Disease (PD) and management remains a challenge. Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties. Objective: To investigate the efficacy of safinamide on NMS and its burden in PD patients with motor fluctuations after 6 months of treatment. Methods: This observational, multicenter, open-label, pilot study assessed a wide range of NMS using the following rating scales, NMSS (non-motor symptom scale), KPPS (King's PD pain scale), HADS (hospital anxiety and depression scale), PDQ-8 (Parkinson's disease quality of life questionnaire), and PDSS-2 (Parkinson's disease sleep scale), EuroQol-5D 3 level version (EQ-5D-3L), CGI-I (clinical global impression of improvement), and PGI-C (patient global impression of change). Motor examination using UPDRS part III (Unified Parkinson's disease rating scale, motor examination), UPDRS IV (complications of therapy) and Hoehn and Yahr staging were also obtained. Results: 27 patients were included in the analysis and were evaluated at baseline and ≥ 6 months after safinamide treatment. 26 patients had a daily maintenance dose of 100 mg and 1 patient a daily dose of 50 mg. Significant improvements in UPDRS IV, KPPS item 5 (region-specific “off” dystonia), KPPS domain 3 (items 4–6, fluctuation related pain) and KPPS total score were observed after treatment with safinamide, while maintaining stable dopaminergic medication. No statistically significant differences were found in NMSS, HADS, PDSS-2, EQ-5D-3L, and PDQ-8 after treatment. Conclusions: Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
glutamate, MAO-B inhibitor, non-motor symptoms, pain, Parkinson's disease, safinamide
in
Brain and Behavior
volume
11
issue
10
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85114086799
  • pmid:34478245
ISSN
2162-3279
DOI
10.1002/brb3.2336
language
English
LU publication?
yes
id
86e85a3c-b9bf-44b2-a253-8b2f2406afc3
date added to LUP
2021-10-07 12:45:12
date last changed
2024-06-16 20:13:46
@article{86e85a3c-b9bf-44b2-a253-8b2f2406afc3,
  abstract     = {{<p>Background: Non-motor symptoms (NMS) are integral to Parkinson's Disease (PD) and management remains a challenge. Safinamide is a novel molecule in relation to addressing NMS due to its multifocal mechanism of action with both dopaminergic and non-dopaminergic properties. Objective: To investigate the efficacy of safinamide on NMS and its burden in PD patients with motor fluctuations after 6 months of treatment. Methods: This observational, multicenter, open-label, pilot study assessed a wide range of NMS using the following rating scales, NMSS (non-motor symptom scale), KPPS (King's PD pain scale), HADS (hospital anxiety and depression scale), PDQ-8 (Parkinson's disease quality of life questionnaire), and PDSS-2 (Parkinson's disease sleep scale), EuroQol-5D 3 level version (EQ-5D-3L), CGI-I (clinical global impression of improvement), and PGI-C (patient global impression of change). Motor examination using UPDRS part III (Unified Parkinson's disease rating scale, motor examination), UPDRS IV (complications of therapy) and Hoehn and Yahr staging were also obtained. Results: 27 patients were included in the analysis and were evaluated at baseline and ≥ 6 months after safinamide treatment. 26 patients had a daily maintenance dose of 100 mg and 1 patient a daily dose of 50 mg. Significant improvements in UPDRS IV, KPPS item 5 (region-specific “off” dystonia), KPPS domain 3 (items 4–6, fluctuation related pain) and KPPS total score were observed after treatment with safinamide, while maintaining stable dopaminergic medication. No statistically significant differences were found in NMSS, HADS, PDSS-2, EQ-5D-3L, and PDQ-8 after treatment. Conclusions: Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients.</p>}},
  author       = {{Sotirios, Grigoriou and Pablo, Martínez Martín and Ray, Chaudhuri K. and Katarina, Rukavina and Valentina, Leta and Denise, Hausbrand and Björn, Falkenburger and Per, Odin and Heinz, Reichmann}},
  issn         = {{2162-3279}},
  keywords     = {{glutamate; MAO-B inhibitor; non-motor symptoms; pain; Parkinson's disease; safinamide}},
  language     = {{eng}},
  number       = {{10}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Brain and Behavior}},
  title        = {{Effects of safinamide on pain in patients with fluctuating Parkinson's disease}},
  url          = {{http://dx.doi.org/10.1002/brb3.2336}},
  doi          = {{10.1002/brb3.2336}},
  volume       = {{11}},
  year         = {{2021}},
}